HCV Drug Resistance
A special issue of Viruses (ISSN 1999-4915).
Deadline for manuscript submissions: closed (30 June 2015) | Viewed by 107231
Special Issue Editor
Interests: hepatology; liver fibrosis; non-alcoholic fatty liver disease (NAFLD); hepatocellular carcinoma; chemoprevention; viral hepatitis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Collegues,
Chronic hepatitis C is a major cause of liver diseases world-wide. These include liver cirrhosis and hepatocellular carcinoma. More than 130 million persons, or about 3% of the world’s population, are chronically infected with the hepatitis C virus (HCV). In the United States, chronic hepatitis C, the most common cause of liver-related death and reason for liver transplantation, recently eclipsed HIV as a cause of mortality. The development of direct-acting antivirals (DAAs) has revolutionized HCV treatment by offering genuine prospects for the first comprehensive cure of a chronic viral infection in man (R. T. Chung and T. F. Baumert, New Engl. J. Med. 2014). While antiviral resistance is a significant challenge for interferon-based therapies, drug resistance in advanced DAA combination therapies appears to be limited to a small fraction of patients. However, distinct genotypes, patients with advanced liver disease and transplantation or patients with HIV-HCV co-infection may pose challenges. In this special issue of Viruses we review mechanisms of antiviral resistance for different class of antiviral drugs, the detection and monitoring of resistance in clinical practice, the clinical impact of resistance in different patient groups and strategies how to prevent and address resistance using complementary antiviral strategies.
Prof. Thomas F. Baumert, MD
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatitis C
- direct-acting antivirals
- interferon
- co-infection
- resistance
- ribavirin
- liver disease
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.